Abiopharma

(30% Negative) Sono-Tek Corp (SOTK) Reports Q1 2026 Financial Results

(70% Positive) Sight Sciences Inc (SGHT) Reports Q1 2026 Financial Results

(90% Positive) Kymera Therapeutics Inc (KYMR) Announces Enrollment Update for medicines Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(90% Positive) uniQure NV (QURE) Announces Enrollment Update for option Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue

(90% Positive) Energous Co (WATT) Reports Q1 2026 Financial Results

(99% Neutral) Bausch Health Companies Inc (BHC) Reports Q1 2026 Financial Results

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

(85% Positive) Onconova Therapeutics Inc. (was merged with Trawsfynydd Therapeutics, Inc. on 02/04/2024) (ONTX) Files Form 8-K

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Sono-Tek Reports Fiscal Third Quarter and Nine-Month Fiscal 2026 Financial Results

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs